Litigation involving drug maker Merck has revealed new information about safety concerns associated with the drug Vioxx, pulled from the market in 2004. Legal documents recently made public show the company found an increased risk in mortality rates during clinical

Which feeder is best for which bulk material? In order to provide customers with accurate answers to this question, Schenck Process are now offering tests at their new, modern TestCenter in Darmstadt that are based on real life situations. The

Isis Pharmaceuticals announced additional results from its ongoing Phase 2 open-label extension study of mipomersen in patients with familial hypercholesterolemia.

Results of a phase IV, open label, head-to-head study of intramuscular AVONEX and high-dose, high-frequency subcutaneous Rebif(R) (interferon beta-1a) provide clinical evidence that the two drugs show similar efficacy over 18 to 30 months of continued therapy in patients with

Action Pharma A/S and Bachem (SWX: BANB) today announced their cooperation on AP214, Action Pharma's lead compound, about to enter Phase 2 clinical trials in post-surgical organ failure. Since 2002, Bachem has supported Action Pharma by producing the peptide activeingredient

Sales grow to CHF198.3 million - up 17.0% in local currencies and 15.5% in CHF respectivelyOperating profit up 29.9%, net income up 37%Operating margin rises sharply to 36.5%, net income margin now at 32.3%Prosposed increase in dividend by 50% to

The Pediatrix Medical Group has completed the acquisition of a pediatric cardiology practice based in Pembroke Pines, Florida, that serves patients in communities in northwest Miami-Dade and western Broward counties.

Novelos Therapeutics has closed a private placement with existing institutional investors resulting in approximately $5.7 million in gross proceeds through the sale of shares of a new series of its convertible preferred stock and warrants to purchase its common stock.

Eye care company Alcon is planning to build a facility in Singapore that will manufacture pharmaceuticals to be distributed throughout most of Asia.

Cell Genesys has reported encouraging data from a completed Phase I/II clinical trial of Gvax immunotherapy in men with recurrent prostate cancer who had not yet received treatment with hormone replacement therapy following relapse after prostate cancer surgery and/or radiation

Teva Pharmaceutical Industries has said that the US District Court for the District of Columbia has granted a request of the company's subsidiary, Teva Pharmaceuticals USA, that the FDA relist generic Risperdal US patent.

Scott & White Hospital has begun recruiting patients with recurring prostate cancer to participate in a clinical trial that involves a prostate specific antigen activated chemical being injected into the prostate that attaches to prostate cancer cells and causes cell

PDI, a provider of commercialization services to the biopharmaceutical industry, has announced the signing of a four-year agreement with Novartis Pharmaceuticals, whereby PDI will deploy a field force to promote a Novartis branded product in the US.

Galderma Pharma has announced that company's US holding company, Galderma Laboratories has completed the acquisition of CollaGenex Pharmaceuticals.

Poniard Pharmaceuticals has reported that an analysis of data from its ongoing phase I clinical trial of oral picoplatin in patients with solid tumors has shown that picoplatin can achieve oral bioavailability of up to 44% in doses tested to

Introgen Therapeutics has reported that Advexin Phase III clinical trial data in patients with recurrent head and neck cancer confirm earlier Phase II results of Advexin efficacy.

U3 Pharma has reported that the preclinical proof-of-concept has been established for its lead product U3-1287, a human anti-HER3 monoclonal antibody.

Novartis Pharmaceuticals has reported new data, which shows that a once-yearly infusion of Reclast injection 5mg was significantly better than risedronate at increasing bone mass in patients with osteoporosis caused by glucocorticoids.

US-based Illumina is making available three new product solutions for cancer research, which include expansion of the company's proprietary DASL Assay to whole-genome profiling, and the launch of DASL-focused expression and methylation profiling on VeraCode technology.

Teva Pharmaceutical Industries has said that the Court of First Instance in Brussels has decided to revoke the Belgium part of Merck Sharp & Dohme's European patent due to lack of inventive step.